Skip to main content
Journal cover image

Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.

Publication ,  Journal Article
Kothe, DL; Decker, JM; Li, Y; Weng, Z; Bibollet-Ruche, F; Zammit, KP; Salazar, MG; Chen, Y; Salazar-Gonzalez, JF; Moldoveanu, Z; Mestecky, J ...
Published in: Virology
March 30, 2007

"Centralized" (ancestral and consensus) HIV-1 envelope immunogens induce broadly cross-reactive T cell responses in laboratory animals; however, their potential to elicit cross-reactive neutralizing antibodies has not been fully explored. Here, we report the construction of a panel of consensus subtype B (ConB) envelopes and compare their biologic, antigenic, and immunogenic properties to those of two wild-type Env controls from individuals with early and acute HIV-1 infection. Glycoprotein expressed from full-length (gp160), uncleaved (gp160-UNC), truncated (gp145), and N-linked glycosylation site deleted (gp160-201N/S) versions of the ConB env gene were packaged into virions and, except for the fusion defective gp160-UNC, mediated infection via the CCR5 co-receptor. Pseudovirions containing ConB Envs were sensitive to neutralization by patient plasma and monoclonal antibodies, indicating the preservation of neutralizing epitopes found in contemporary subtype B viruses. When used as DNA vaccines in guinea pigs, ConB and wild-type env immunogens induced appreciable binding, but overall only low level neutralizing antibodies. However, all four ConB immunogens were significantly more potent than one wild-type vaccine at eliciting neutralizing antibodies against a panel of tier 1 and tier 2 viruses, and ConB gp145 and gp160 were significantly more potent than both wild-type vaccines at inducing neutralizing antibodies against tier 1 viruses. Thus, consensus subtype B env immunogens appear to be at least as good as, and in some instances better than, wild-type B env immunogens at inducing a neutralizing antibody response, and are amenable to further improvement by specific gene modifications.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Virology

DOI

ISSN

0042-6822

Publication Date

March 30, 2007

Volume

360

Issue

1

Start / End Page

218 / 234

Location

United States

Related Subject Headings

  • Virology
  • Viral Envelope Proteins
  • Vaccines, DNA
  • Species Specificity
  • Sequence Alignment
  • Neutralization Tests
  • Molecular Sequence Data
  • Injections, Intramuscular
  • Immunization
  • Immune Sera
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kothe, D. L., Decker, J. M., Li, Y., Weng, Z., Bibollet-Ruche, F., Zammit, K. P., … Hahn, B. H. (2007). Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology, 360(1), 218–234. https://doi.org/10.1016/j.virol.2006.10.017
Kothe, Denise L., Julie M. Decker, Yingying Li, Zhiping Weng, Frederic Bibollet-Ruche, Kenneth P. Zammit, Maria G. Salazar, et al. “Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.Virology 360, no. 1 (March 30, 2007): 218–34. https://doi.org/10.1016/j.virol.2006.10.017.
Kothe DL, Decker JM, Li Y, Weng Z, Bibollet-Ruche F, Zammit KP, et al. Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology. 2007 Mar 30;360(1):218–34.
Kothe, Denise L., et al. “Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.Virology, vol. 360, no. 1, Mar. 2007, pp. 218–34. Pubmed, doi:10.1016/j.virol.2006.10.017.
Kothe DL, Decker JM, Li Y, Weng Z, Bibollet-Ruche F, Zammit KP, Salazar MG, Chen Y, Salazar-Gonzalez JF, Moldoveanu Z, Mestecky J, Gao F, Haynes BF, Shaw GM, Muldoon M, Korber BTM, Hahn BH. Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology. 2007 Mar 30;360(1):218–234.
Journal cover image

Published In

Virology

DOI

ISSN

0042-6822

Publication Date

March 30, 2007

Volume

360

Issue

1

Start / End Page

218 / 234

Location

United States

Related Subject Headings

  • Virology
  • Viral Envelope Proteins
  • Vaccines, DNA
  • Species Specificity
  • Sequence Alignment
  • Neutralization Tests
  • Molecular Sequence Data
  • Injections, Intramuscular
  • Immunization
  • Immune Sera